The metabolic syndrome: Evolving evidence that thiazolidinediones provide rational therapy

Diabetes, Obesity and Metabolism

Volumn 8, Issue 4, 2006, Pages 365-380

  Wyne, Kathleen L ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Insulin resistance; Metabolic syndrome; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EXENDIN 4; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; RAMIPRIL; RIMONABANT; ROSIGLITAZONE; SIMVASTATIN; TELMISARTAN; TRIACYLGLYCEROL; TROGLITAZONE; VALSARTAN;

ANTIINFLAMMATORY ACTIVITY; BODY FAT DISTRIBUTION; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DYSLIPIDEMIA; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FLUID RETENTION; HEART FAILURE; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; LIVER TOXICITY; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 33748442637     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00522.x     Document Type: Review

References (169)

1. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
2. Kylin E. Studien ueber das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt Fuer Innere Med 1923; 44: 105-127.
3. Björntorp P. Metabolic implications of body fat distribution. Diabetes Care 1991; 14: 1132-1143.
4. Reaven GM. Role of insulin resistance in the pathophysiology of non-insulin dependent diabetes mellitus. Diabet Metab Rev 1993; 9 (Suppl. 1): 5S-12S.
5. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: Evidence for a common antecedent? Diabetes Care 1999; 22 (Suppl. 3): C25-C30.
6. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
7. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
8. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
9. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2003; 163: 427-436.
10. Cruz ML, Weigensberg MJ, Huang TTK, Ball G, Shaibi GQ, Goran MI. The metabolic syndrome in overweight Hispanic youth and the role of insulin sensitivity. J Clin Endocrinol Metab 2004; 89: 108-113.
11. Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
13. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association, National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
14. Grundy SM, Hansen B, Smith SC Jr et al. American Heart Association, National Heart, Lung and Blood Institute, American Diabetes Association. Clinical management of metabolic syndrome: Report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation 2004; 109: 551-556.
15. Wilson PWF, Grundy SM. The metabolic syndrome. Practical guide to origins and treatment: Part I. Circulation 2003; 108: 1422-1425.
16. Wilson PWF, Grundy SM. The metabolic syndrome. A practical guide to origins and treatment: Part II. Circulation 2003; 108: 1537-1540.
17. Fagot-Campagna A, Pettitt DJ, Engelgau MM et al. Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr 2000; 136: 664-672.
18. Trevino RP, Pugh JA, Hernandez AE, Menchaca VD, Ramirez RR, Mendoza M. Bienestar: A diabetes risk-factor prevention program. J Sch Health 1998; 68: 62-67.
19. DeFronzo RA. Lilly lecture 1987. The triumvirate: Beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
20. Bell GI, Polonsky KS. Diabetes mellitus and genetically programmed defects in beta-cell function. Nature 2001; 414: 788-791.
21. Hotu S, Carter B, Watson PD, Cutfield WS, Cundy T. Increasing prevalence of type 2 diabetes in adolescents. J Paediatr Child Health 2004; 40: 201-204.
22. McMahon SK, Haynes A, Ratnam N et al. Increase in type 2 diabetes in children and adolescents in Western Australia. Med J Aust 2004; 180: 459-461.
23. Moore KR, Harwell TS, McDowall JM, Helgerson SD, Gohdes D. Three-year prevalence and incidence of diabetes among American Indian youth in Montana and Wyoming, 1999 to 2001. J Pediatr 2003; 143: 368-371.
24. Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care 1999; 22: 345-354.
25. Wabitsch M, Hauner H, Hertrampf M et al. Type II diabetes mellitus and impaired glucose regulation in Caucasian children and adolescents with obesity living in Germany. Int J Obes Relat Metab Disord 2004; 28: 307-313.
26. Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM. National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003; 290: 1345-1350.
27. Weiss R, Dziura J, Burgert TS et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350: 2362-2374.
28. Colditz GA, Willett WC, Stampfer MJ et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol 1990; 132: 501-513.
29. Després J-P, Lemieux I, Prud'homme D. Treatment of obesity: Need to focus on high risk abdominally obese patients. BMJ 2001; 322: 716-720.
30. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD. The visceral adiposity syndrome in Japanese-American men. Obes Res 1994; 2: 364-371.
31. Wajchenberg BL, Giannella-Neto D, da Silva MER, Santos RF. Depot-specific hormonal characteristics of subcutaneous and visceral adipose tissue and their relation to the metabolic syndrome. Horm Metab Res 2002; 34: 616-621.
32. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 2003; 92 (4A): 27J-33J.
33. Axelsen M, Smith U, Eriksson JW, Taskinen M-R, Jansson P-A. Postprandial hypertriglyceridemia and insulin resistance in normoglycemic first-degree relatives of patients with type 2 diabetes. Ann Intern Med 1999; 131: 27-31.
34. Paolisso G, Tagliamonte MR, Rizzo MR et al. Lowering fatty acids potentiates acute insulin response in first degree relatives of people with type II diabetes. Diabetologia 1998; 41: 1127-1132.
35. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2595-2600.
36. Mokdad AH, Ford ES, Bowman BA. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003; 289: 76-79.
37. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM: A balanced overview. Diabetes Care 1992; 15: 318-368.
38. Petersen KF, Shulman GI. Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus. Am J Cardiol 2002; 90 (Suppl. 5A): 11G-18G.
39. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
40. Boden G, Chen X, Ruiz J, White JV, Rossetti L. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93: 2438-2446.
41. Gordon ES. Non-esterified fatty acids in blood of obese and lean subjects. Am J Clin Nutr 1960; 8: 740-747.
42. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 1988; 37: 1020-1024.
43. Roden M, Price TB, Perseghin G et al. Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 1996; 97: 2859-2865.
44. Sivan E, Homko CJ, Whittaker PG, Reece EA, Chen X, Boden G. Free fatty acids and insulin resistance during pregnancy. J Clin Endocrinol Metab 1998; 83: 2338-2342.
45. Boden G, Chen X, Rosner J, Barton M. Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995; 44: 1239-1242.
46. Boden G, Chen X. Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest 1995; 96: 1261-1268.
47. Dresner A, Laurent D, Marcucci M et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
48. Santomauro AT, Boden G, Silva ME et al. Overnight lowering of free fatty acids with acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 1999; 48: 1836-1841.
49. Bluher M, Kratzsch J, Paschke R. Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 2001; 24: 328-334.
50. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
51. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2783-2791.
52. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001; 44: 2210-2219.
53. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, Unger RH. βgr;-Cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-βgr;-cell relationships. Proc Natl Acad Sci USA 1994; 91: 10878-10882.
54. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-336.
55. Shimabukuro M, Ohneda M, Lee Y, Unger RH. Role of nitric oxide obesity-induced βgr;-cell disease. J Clin Invest 1997; 100: 290-295.
56. Finegood DT, McArthur MD, Kojwang D et al. βgr;-cell mass dynamics in Zucker diabetic fatty rats: Rosiglitazone prevents the rise in net cell death. Diabetes 2001; 50: 1021-1029.
57. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998; 273: 3547-3550.
58. Unger RH, Orci L. Diseases of liporegulation: New perspective on obesity and related disorders. FASEB J 2001; 15: 312-321.
59. Ye JM, Dzamko N, Cleasby ME et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: Comparison with metformin. Diabetologia 2004; 47: 1306-1313.
60. Carey DG, Cowin GJ, Galloway GJ et al. Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-1015. [erratum appears in Obes Res 2002; 10: 1095]
61. Kelley DE, McKolanis TM, Kelley CA. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes 2002; 51 (Suppl. 2): A35. [abstract]
62. Lupi R, Del Guerra S, Marselli L et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: Evidence for a role of PPARgamma2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab 2004; 286: E560-E567.
63. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002; 25: 1129-1134.
64. Norhammar A, Tenerz A, Nilsson G et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. Lancet 2002; 359: 2140-2144.
65. Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
66. Festa A, D'Agostino R Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: The Insulin Resistance Atherosclerosis Study. Kidney Int 2000; 58: 1703-1710.
67. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
68. Girman CJ, Rhodes T, Mercuri M et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
69. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004; 109: 42-46.
70. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals: Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.
71. Haffner SM, Mykkanen L, Valdez RA et al. Disproportionately increased proinsulin levels are associated with the insulin resistance syndrome. J Clin Endocrinol Metab 1994; 79: 1806-1810.
72. Haffner SM, Hanley AJ. Do increased proinsulin concentrations explain the excess risk of coronary heart disease in diabetic and prediabetic subjects? Circulation 2002; 105: 2008-2009.
73. Yudkin JS. Increased proinsulin concentrations and excess risk of coronary heart disease in patients with diabetes and prediabetes. Circulation 2002; 106: E202.
74. Yudkin JS, May M, Elwood P et al. Concentrations of proinsulin like molecules predict coronary heart disease risk independently of insulin: prospective data from the Caerphilly Study. Diabetologia 2002; 45: 327-336.
75. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50years and older. Diabetes 2003; 52: 1210-1214.
76. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004; 27 (Suppl. 1): S15-S35.
77. Davidson MB. Clinical implications of insulin resistance syndromes. Am J Med 1995; 99: 420-426.
78. Carey DG, Jenkins AB, Campbell LV, Freund J, Chisholm DJ. Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996; 45: 633-638.
79. Fontbonne AM, Eschwège EM. Insulin and cardiovascular disease: Paris Prospective Study. Diabetes Care 1991; 14: 461-469.
80. Fujimoto WY, Leonetti DL, Kinyoun JL et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes 1987; 36: 721-729.
81. Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med 2000; 108: 9S-14S.
82. Carey VJ, Walters EE, Colditz GA et al. Body fat distribution and risk of non-insulin-dependent diabetes mellitus in women. The Nurses' Health Study. Am J Epidemiol 1997; 145: 614-619.
83. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-2282.
84. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
85. Fontbonne A, Eschwège E, Cambien F et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes: Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia 1989; 32: 300-304.
86. Grundy SM, Benjamin IJ, Burke GL et al. Diabetes and cardiovascular disease: A statement for healthcare professionals from the American Heart Association. Circulation 1999; 100: 1134-1146.
87. Lamarche B, Tchernof A, Moorjani S et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Québec Cardiovascular Study. Circulation 1997; 95: 69-75.
88. Mitchell BD, Haffner SM, Hazuda HP, Valdez R, Stern MP. The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. Am J Epidemiol 1992; 136: 12-22.
89. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-458.
90. Sunayama S, Watanabe Y, Daida H, Yamaguchi H. Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. Curr Opin Lipidol 2000; 11: 397-402.
91. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003; 139: 802-809.
92. Freed MI, Ratner R, Marcovina SM et al. On behalf of the Rosiglitazone Study 108 Investigators. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952.
93. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713. [erratum appears in BMJ 1999; 318: 29]
94. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374-381.
95. Fullert S, Schneider F, Haak E et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: A double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506.
96. Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003; 26: 172-178.
97. Meigs JB, Mittleman MA, Nathan DM et al. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: The Framingham Offspring Study. JAMA 2000; 283: 221-228.
98. Lindahl B, Dinesen B, Eliasson M, Roder M, Hallmans G, Stegmayr B. High proinsulin levels precede first-ever stroke in a nondiabetic population. Stroke 2000; 31: 2936-2941.
99. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
100. Bellelli G, Rozzini R, Battista Frisoni G, Trabucchi M. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 2107 (Letter).
101. Freeman DJ, Norrie J, Caslake MJ et al. West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600.
102. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE. Inflammatory markers and risk of developing type 2 diabetes in women. Diabetes 2004; 53: 693-700.
103. Nakanishi S, Yamane K, Kamei N, Okubo M, Kohno N. Elevated c-reactive protein is a risk factor for the development of type 2 diabetes in Japanese Americans. Diabetes Care 2003; 26: 2754-2757.
104. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
105. Spranger J, Kroke A, Mohlig M et al. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003; 52: 812-817.
106. Sung KC, Suh JY, Kim BS et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16: 429-433.
107. Tan KC, Wat NM, Tam SC, Janus ED, Lam TH, Lam KS. C-reactive protein predicts the deterioration of glycemia in Chinese subjects with impaired glucose tolerance. Diabetes Care 2003; 26: 2323-2328.
108. Thorand B, Lowel H, Schneider A et al. C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: Results from the MONICA Augsburg cohort study, 1984-1998. Arch Intern Med 2003; 163: 93-99.
109. Libby P. Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-2850.
110. Ross R. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340: 115-126.
111. Frohlich M, Imhof A, Berg G et al. Association between C-reactive protein and features of the metabolic syndrome: A population-based study. Diabetes Care 2000; 23: 1835-1839.
112. Haffner SM, D'Agostino R Jr, Mykkanen L et al. Insulin sensitivity in subjects with type 2 diabetes: Relationship to cardiovascular risk factors. The Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568.
113. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979 (Erratum appears in N Engl J Medical 1997; 337: 356).
114. Haffner SM, Mykkanen L, Festa A, Burke JP, Stern MP. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: Implications for preventing coronary heart disease during the prediabetic state. Circulation 2000; 101: 975-980.
115. Messerli AW, Seshadri N, Pearce GL, Sachar R, Hoogwerf BJ, Sprecher DL. Relation of albumin/creatinine ratio to c-reactive protein and to the metabolic syndrome. Am J Cardiol 2003; 92: 610-612.
116. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002; 51: 455-461.
117. Lowe G, Rumley A, Norrie J et al. Blood rheology, cardiovascular risk factors, and cardiovascular disease: The West of Scotland Coronary Prevention Study. Thromb Haemost 2000; 84: 553-558 (Erratum appears in Thromb Haemost 2001; 85: 946).
118. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT Diabetes Study. Diabetes Care 1997; 20: 537-544.
119. Tuomilehto J, Lindstrom J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350.
120. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26: 977-980.
121. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 2002; 359: 2072-2077.
122. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796-2803.
123. Scheen AJ. Prevention of type 2 diabetes in obese patients: First results with orlistat in the XENDOS study. Rev Med Liege 2002; 57: 617-621 (In French).
124. Sjostrom CD, Peltonen M, Wedel H, Sjostrom L. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000; 36: 20-25.
125. The Captopril Prevention Project (CAPP) Study Group. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial. Curr Hypertens Rep 1999; 1: 466-467.
126. Freeman DJ, Norrie J, Sattar N et al. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001; 103: 357-362.
127. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Studies of Left Ventricular Dysfunction, Enalapril reduces the incidence of diabetes in patients with chronic heart failure: Insight from the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 2003; 107: 1291-1296.
128. Yusuf S, Gerstein H, Hoogwerf B et al. HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-1885.
129. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
130. Julius S, Kjeldsen SE, Brunner H et al. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544-548.
131. Doggrell SA. Telmisartan: Killing two birds with one stone. Expert Opin Pharmacother 2004; 5: 2397-2400.
132. Yamagishi S, Takeuchi M. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 2005; 64: 476-478.
133. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-1669.
134. Sun L, Halaihel N, Zhang W, Rogers T, Levi M. Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 2002; 277: 18919-18927.
135. Chiquette E, Ramirez G, DeFronzo R, A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104.
136. Stolar MW, Chilton RJ. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003; 25 (Suppl. B): B4-B31.
137. Baba S. Pioglitazone: A review of Japanese clinical stud ies. Curr Med Res Opin 2001; 17: 166-189.
138. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; The Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288 (Erratum appears in J Clin Endocrinol Metab 2001; 86: 1659).
139. Ovalle F, Bell DSH. Effect of thiazolidinediones on high-density lipoprotein subfractions. Endocr Pract 2002; 8: 102-104.
140. Herz M, Johns D, Reviriego J et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1074-1095.
141. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003; 17: 7-12.
142. Ghazzi MN, Perez JE, Antonucci TK et al. The Troglitazone Study Group. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997; 46: 433-439.
143. Sarafidis PA, Lasaridis AN, Nilsson PM et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1769-1777.
144. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215-222.
145. Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care 2000; 23: 1067-1071.
146. Arioglu E, Duncan-Morin J, Sebring N et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133: 263-274.
147. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance. Diabetologia 1987; 30: 698-702.
148. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001; 21: 1082-1099.
149. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002; 4: 56-59.
150. Smith SA, Porter LE, Biswas N, Freed MI. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:iNsulin ratio in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 6048-6053.
151. Alssema M, Dekker JM, Nijpels G, Stehouwer CD, Bouter LM, Heine RJ. Proinsulin concentration is an independent predictor of all-cause and cardiovascular mortality: An 11-year follow-up of the Hoorn Study. Diabetes Care 2005; 28: 860-865.
152. Fonseca VA, Reynolds T, Hemphill D et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 181-186.
153. Hsueh WA, Law RE. PPARgamma and atherosclerosis: Effects on cell growth and movement. Arterioscler Thromb Vasc Biol 2001; 21: 1891-1895.
154. Dandona P. Endothelium, inflammation, and diabetes. Curr Diab Rep 2002; 2: 311-315.
155. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004; 89: 2728-2735.
156. Avena R, Mitchell ME, Nylen ES, Curry KM, Sidawy AN. Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes. J Vasc Surg 1998; 28: 1024-1032.
157. Natali A, Baldeweg S, Toschi E et al. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 2004; 27: 1349-1357.
158. Pistrosch F, Passauer J, Fischer S, Fuecker K, Hanefeld M, Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-490.
159. Wang TD, Chen WJ, Lin JW, Chen MF, Lee YT. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. Am J Cardiol 2004; 93: 362-365.
160. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y. Rapid communication: Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 3452-3456.
161. Minamikawa J, Tanaka S, Yamauchi M, Inoue D, Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820.
162. Actos prescribing information. Lincolnshire, IL: Takeda Pharmaceuticals America, Inc; 2004.
163. Avandia prescribing information. Philadelphia, PA: GlaxoSmithKline, 2003.
164. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-1702 (Erratum appears in JAMA 2000; 284: 1384).
165. Gomez-Perez FJ, Fanghanel-Salmon G, Barbosa JA et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002; 18: 127-134.
166. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: Evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
167. Rubin C, Schneider R. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials. Diabetes 2000; 49 (Suppl. 1): A123 (Abstract).
168. Stumvoll M. Thiazolidinediones: Some recent developments. Expert Opin Investig Drugs 2003; 12: 1179-1187.
169. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64: 2537-2565.